1 Min Read
Sept 15 (Reuters) - ROCHE HOLDING AG:
* FDA HAS REQUESTED THAT A PHASE IB AND A PHASE IB/II TECENTRIQ STUDY BE PLACED ON PARTIAL CLINICAL HOLD Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.